Perspective Therapeutics (CATX) Inventory Average (2011 - 2023)
Perspective Therapeutics' (CATX) quarterly Inventory Average came in at $1.1 million in Q3 2023, down 28.55% year-over-year from $1.5 million in Q3 2022, and down 15.79% quarter-over-quarter from $1.3 million in Q2 2023.
Analysis
Perspective Therapeutics (CATX) Inventory Average (2011 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Inventory Average across 12 years of filings, most recently posting $1.1 million for Q3 2023.
- In Q3 2023, Inventory Average fell 28.55% year-over-year to $1.1 million; the TTM figure through Sep 2023 stood at $1.1 million (down 28.55% YoY), while the FY2022 annual figure was $1.4 million, changed N/A from the prior year.
- Inventory Average came in at $1.1 million for Q3 2023 at Perspective Therapeutics, down from $1.3 million in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $1.5 million in Q4 2022 to a low of $513500.0 in Q1 2019.
- Average Inventory Average over 5 years is $908184.2, with a median of $855500.0 recorded in 2021.
- Year-over-year, Inventory Average surged 62.94% in 2021 and slipped 28.55% in 2023.
- Over 5 years, Inventory Average stood at $523000.0 in 2019, then grew by 24.86% to $653000.0 in 2020, then surged by 62.94% to $1.1 million in 2021, then surged by 39.19% to $1.5 million in 2022, then slipped by 28.87% to $1.1 million in 2023.
- Per Business Quant data, the three most recent Inventory Average figures were $1.1 million in Q3 2023, $1.3 million in Q2 2023, and $1.4 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.09 Bn | 193.10 Bn | 7.24 Bn | 6.20 Bn |
| 2 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | 1.93 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 1.77 Bn |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.79 Bn | 3.93 Bn | 3.09 Bn |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.35 Bn | 48.21 Bn | 52.00 Mn | 213.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.40 Bn | 30.10 Bn | 992.69 Mn | 90.57 Mn |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn | 2.17 Bn |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 340.24 Mn | 340.24 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.48 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 1.28 Mn |
| Mar 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 1.06 Mn |
| Sep 30, 2021 | 1.02 Mn |
| Jun 30, 2021 | 855,500.00 |
| Mar 31, 2021 | 698,000.00 |
| Dec 31, 2020 | 653,000.00 |
| Sep 30, 2020 | 643,000.00 |
| Jun 30, 2020 | 612,500.00 |
| Mar 31, 2020 | 562,500.00 |
| Dec 31, 2019 | 523,000.00 |
| Sep 30, 2019 | 515,500.00 |
| Jun 30, 2019 | 531,500.00 |
| Mar 31, 2019 | 513,500.00 |
| Dec 31, 2018 | 490,500.00 |